KORU Medical Systems to Participate in the Canaccord Genuity 44th Annual Growth Conference

Rhea-AI Summary

KORU Medical Systems (NASDAQ: KRMD), a leading medical technology company specializing in large volume subcutaneous infusion solutions, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for August 14, 2024, with KORU Medical's management set to present at 8:30 am ET.

Interested parties can access both the live and archived webcast of the presentation through the News/Events page in the Investors section of KORU Medical's official website at www.korumedical.com. This conference provides an opportunity for KORU Medical to showcase its innovative and patient-centric solutions to a wider audience of investors and industry professionals.

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the Canaccord Genuity 44^th Annual Growth Conference on August 14, 2024.

KORU Medical's management is scheduled to present at the Canaccord Genuity 44^th Annual Growth Conference on August 14, 2024, at 8:30 am ET. Interested parties can access the live and archived webcast on the News/Events page of the Investors section of KORU Medical’s website at www.korumedical.com.

About KORU Medical Systems

KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60^® and FreedomEdge^® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240725462010/en/

Investor Contact:

Greg Chodaczek

347-620-7010

investor@korumedical.com

Source: KORU Medical Systems

FAQ

When is KORU Medical Systems (KRMD) presenting at the Canaccord Genuity 44th Annual Growth Conference?

KORU Medical Systems (KRMD) is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024, at 8:30 am ET.

How can I watch KORU Medical Systems' (KRMD) presentation at the Canaccord Genuity conference?

You can watch the live and archived webcast of KORU Medical Systems' (KRMD) presentation on the News/Events page of the Investors section on their website at www.korumedical.com.

What is the main focus of KORU Medical Systems (KRMD)?

KORU Medical Systems (KRMD) is a medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions.

What stock exchange is KORU Medical Systems (KRMD) listed on?

KORU Medical Systems (KRMD) is listed on the NASDAQ stock exchange.